Investors

Overview

Corporate Profile

Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of dimethyl fumarate (DMF) for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the recent Settlement and License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on sales of Tecfidera® or other DMF products for MS, dependent on, among other things, successfully appealing the U.S. interference and a favorable outcome in Europe with respect to the EP2801355 opposition proceeding.


Most Recent Presentation
Download Documentation Corporate Presentation

Stock Information
FWP (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Financial Status IndicatorC
Price$4.73
Change (%) Stock is Up 0.45 (10.51%)
Volume11,864
Data as of 11/17/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock chart for: FWP.OQ.  Currently trading at $4.73 with a 52 week high of $9.67 and a 52 week low of $2.70.

Recent NewsMore >>
DateTitle 
11/09/17Forward Pharma to Participate in the Nordic-American Life Science Conference
COPENHAGEN, Denmark, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the Nordic-American Life Science Conference being held November 13-14, 2017 in New York, NY. Dr. Svendsen will speak on the CXO Panel on Monday, November 13, 2017 at 9:00 AM ET and host one-on-one meetings. About Forward Pharma: Forward Pharma A/S is a Danish biopharmaceutical company tha... 
Printer Friendly Version
09/26/17Forward Pharma Reports Financial and Operational Results from the First Six Months of 2017
COPENHAGEN, Denmark, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We” or “Forward” or the “Company”), today reported financial results for the six-month period ended June 30, 2017.  Net income for the six-month period ended June 30, 2017 was $941.2 million, or $1.91 per diluted share, versus net loss of $(32.0) million, or $(0.07) per share for the six-month period ended June 30, 2016.  “We are pleased to announce our results for the first half year of 2017, where majo... 
Printer Friendly Version
09/05/17Forward Pharma Files Opening Brief in the Appeal of the U.S. Patent Interference to the Federal Circuit
COPENHAGEN, Denmark, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced the filing in the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) of the opening brief for the appeal of the PTAB decision that ended the interference proceeding between the Forward 11/576,871 patent application (the “’871 application”) and an issued Biogen patent. “We continue to believe that our intellectual property is strong and that ... 
Printer Friendly Version
09/01/17Forward Pharma Board of Directors Approves Capital Reduction and Returns EUR 917.7 Million to Shareholders
COPENHAGEN, Denmark, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“the Company” or “Forward”) today announced the final approval by the Company’s board of directors of the plans to return a total of EUR 917.7 million to its shareholders through a capital reduction (the “Capital Reduction”). On September 1, 2017, following this approval, the Company effected the Capital Reduction with a distribution of proceeds to holders of ordinary shares. The record date for holders... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Forward Pharma A/S posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources